vimarsana.com
Home
Live Updates
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and ... : vimarsana.com
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and ...
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022
Related Keywords
Japan ,
Canada ,
United States ,
America ,
David Schull ,
Richardj Daly ,
Mary Coleman ,
Dydo Pharma Inc ,
Catalyst Pharmaceuticals Inc ,
Catalyst Or Company Nasdaq ,
Drug Application To Japan Pharmaceuticals ,
Mcap Companies ,
Devices Agency ,
Health Canada ,
International Number ,
Exchange Commission On ,
Achieved Record ,
Increase Compared ,
Record Fourth Quarter ,
Fourth Quarter ,
Neuroscience Commercial Portfolio ,
Revenues Guidance ,
Year Ended December ,
Net Product ,
Income Per Share ,
Full Year ,
Steven Miller ,
Executive Vice President ,
Chief Operating ,
Scientific Officer ,
Jeffrey Del Carmen ,
Chief Commercial Officer ,
Michael Kalb ,
Chief Financial ,
Dydo Pharma ,
New Drug Application ,
Medical Devices Agency ,
Most Successful Small Cap ,
Annual Epilepsy Awareness ,
Annual Report ,
Exchange Commission ,
Canada Dial In Number ,
Dial In Number ,
Catalyst Pharmaceuticals ,
North America ,
Duchenne Muscular ,
Fast Track ,
Full Prescribing ,
Safety Information ,
Full Prescribing Information ,
Three Months ,
Investor Contact Mary Coleman ,
Contact David Schull ,
Russo Partners ,
vimarsana.com © 2020. All Rights Reserved.